A Genetic Variant in the Body's Cannabis Receptor Was Linked to Higher Rheumatoid Arthritis Risk

In an Iranian population, carriers of the RR genotype in the cannabinoid CB2 receptor gene had more than 2.5 times the risk of developing rheumatoid arthritis compared to other genotypes.

Nateghi, Ali et al.·International journal of genomics·2025·Preliminary EvidenceCase-Control
RTHC-07238Case ControlPreliminary Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Case-Control
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Logistic regression revealed significant associations between the Q63R polymorphism in the CNR2 gene and rheumatoid arthritis under codominant, dominant, and additive inheritance models. Carriers of the RR genotype had more than a 2.5-fold increased risk of developing RA.

Key Numbers

120 RA patients; 120 healthy controls; RR genotype associated with >2.5-fold increased RA risk; significant associations under codominant, dominant, and additive models; TaqMan assay genotyping.

How They Did This

Case-control study of 120 RA patients and 120 healthy controls in Iran, genotyped for the Q63R polymorphism using TaqMan assay. Multiple genetic inheritance models (codominant, dominant, recessive, overdominant, additive) were analyzed using SNPStats software.

Why This Research Matters

The endocannabinoid system plays a role in immune regulation, and genetic variations in cannabinoid receptors could predispose individuals to autoimmune diseases. This study is the first to examine this specific genetic association in an Iranian population.

The Bigger Picture

If cannabinoid receptor genetics influence autoimmune disease risk, it could open new avenues for understanding why some people develop conditions like RA and whether cannabinoid-based interventions could help manage autoimmune inflammation in genetically susceptible individuals.

What This Study Doesn't Tell Us

Small sample size (120 per group) limits statistical power. Single ethnic population limits generalizability. No functional studies to explain how the Q63R variant affects CB2 receptor function or immune regulation. Cannot establish causation from genetic association alone.

Questions This Raises

  • ?Does this genetic variant affect how patients respond to cannabinoid-based treatments?
  • ?Would larger, multi-ethnic studies replicate this association?
  • ?What is the functional mechanism by which Q63R alters immune regulation?

Trust & Context

Key Stat:
CB2 receptor RR genotype linked to 2.5x higher rheumatoid arthritis risk
Evidence Grade:
Preliminary: Small case-control study (240 total) in a single ethnic population, representing the first investigation of this association in Iranians.
Study Age:
Published in 2025.
Original Title:
Association of Cannabinoid CB2 Receptor Q63R Variant With Rheumatoid Arthritis in an Iranian Cohort.
Published In:
International journal of genomics, 2025, 6182868 (2025)
Database ID:
RTHC-07238

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-ControlFollows or compares groups over time
This study
Cross-Sectional / Observational
Case Report / Animal Study

Compares people with a condition to similar people without it.

What do these levels mean? →

Frequently Asked Questions

What is the CB2 receptor?

CB2 is one of two main cannabinoid receptors in the body. Unlike CB1 (found mainly in the brain), CB2 is primarily found on immune cells and plays a role in regulating inflammation and immune responses. It's part of the endocannabinoid system.

Does this mean cannabis could treat rheumatoid arthritis?

The study shows a genetic link between a cannabinoid receptor variant and RA risk, suggesting the endocannabinoid system plays a role in RA. However, this does not directly demonstrate that cannabis or cannabinoids would treat the disease. More research is needed to understand the functional implications.

Read More on RethinkTHC

Cite This Study

RTHC-07238·https://rethinkthc.com/research/RTHC-07238

APA

Nateghi, Ali; Zamani, Samin; Tahamtan, Alireza. (2025). Association of Cannabinoid CB2 Receptor Q63R Variant With Rheumatoid Arthritis in an Iranian Cohort.. International journal of genomics, 2025, 6182868. https://doi.org/10.1155/ijog/6182868

MLA

Nateghi, Ali, et al. "Association of Cannabinoid CB2 Receptor Q63R Variant With Rheumatoid Arthritis in an Iranian Cohort.." International journal of genomics, 2025. https://doi.org/10.1155/ijog/6182868

RethinkTHC

RethinkTHC Research Database. "Association of Cannabinoid CB2 Receptor Q63R Variant With Rh..." RTHC-07238. Retrieved from https://rethinkthc.com/research/nateghi-2025-association-of-cannabinoid-cb2

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.